Our research laboratory uses proteomics to develop innovative cancer screening tools. Proteomics is the study of proteins, which are essential for the functioning of cells in the human body. By analyzing the proteins present in tears, we can identify unique biomarkers that indicate the presence of cancer. Our proteomics-based approach allows for earlier detection of cancer, which is crucial for effective treatment and improved patient outcomes.
The Clinical Laboratory Improvement Amendment (CLIA) passed in 1988 was established to provide quality standards, strengthen Federal oversight of clinical laboratories, and ensure the reliability and accuracy of patient test results. This program allows clinical labs to develop and validate their own testing protocols which can only be run in the lab where the protocol was validated.
The qualification for a laboratory director of high complexity testing at 42 CFR 493.1443(b)(3)(i) is that the laboratory director must hold an earned doctoral degree in a chemical, physical, biological or clinical laboratory science from an accredited institution and be certified and continue to be certified by a board approved by HHS.
We’re a revenue stage biotech company with big ideas, and the science to make them happen.
Be a part of the future of cancer screening.
1905 E Mission Blvd. Suite 6 Fayetteville, AR 72703 479-334-2828